JP5303279B2 - アルファ７ニコチン性受容体に対する抗体を使用した炎症性疾患の治療 - Google Patents

アルファ７ニコチン性受容体に対する抗体を使用した炎症性疾患の治療 Download PDF

Info

Publication number
JP5303279B2
JP5303279B2 JP2008541306A JP2008541306A JP5303279B2 JP 5303279 B2 JP5303279 B2 JP 5303279B2 JP 2008541306 A JP2008541306 A JP 2008541306A JP 2008541306 A JP2008541306 A JP 2008541306A JP 5303279 B2 JP5303279 B2 JP 5303279B2
Authority
JP
Japan
Prior art keywords
antibody
seq
fragment
antigen
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008541306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009515982A5 (enExample
JP2009515982A (ja
Inventor
ヤン，リーホン
トレーシー，ケビン，ジェイ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Feinstein Institutes for Medical Research
Original Assignee
Feinstein Institutes for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Feinstein Institutes for Medical Research filed Critical Feinstein Institutes for Medical Research
Publication of JP2009515982A publication Critical patent/JP2009515982A/ja
Publication of JP2009515982A5 publication Critical patent/JP2009515982A5/ja
Application granted granted Critical
Publication of JP5303279B2 publication Critical patent/JP5303279B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L12/00—Data switching networks
    • H04L12/02—Details
    • H04L12/16—Arrangements for providing special services to substations
    • H04L12/18—Arrangements for providing special services to substations for broadcast or conference, e.g. multicast
    • H04L12/1813—Arrangements for providing special services to substations for broadcast or conference, e.g. multicast for computer conferences, e.g. chat rooms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/04—Real-time or near real-time messaging, e.g. instant messaging [IM]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Neurosurgery (AREA)
  • Multimedia (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
JP2008541306A 2005-11-15 2006-11-15 アルファ７ニコチン性受容体に対する抗体を使用した炎症性疾患の治療 Expired - Fee Related JP5303279B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73704505P 2005-11-15 2005-11-15
US60/737,045 2005-11-15
PCT/US2006/044329 WO2007059203A2 (en) 2005-11-15 2006-11-15 Treating inflammatory disorders with antibodies to the alpha-7 nicotinic receptors

Publications (3)

Publication Number Publication Date
JP2009515982A JP2009515982A (ja) 2009-04-16
JP2009515982A5 JP2009515982A5 (enExample) 2010-01-14
JP5303279B2 true JP5303279B2 (ja) 2013-10-02

Family

ID=38007280

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008541306A Expired - Fee Related JP5303279B2 (ja) 2005-11-15 2006-11-15 アルファ７ニコチン性受容体に対する抗体を使用した炎症性疾患の治療

Country Status (7)

Country Link
US (2) US8316104B2 (enExample)
EP (1) EP1957107A2 (enExample)
JP (1) JP5303279B2 (enExample)
CN (1) CN101355967A (enExample)
AU (1) AU2006315420B2 (enExample)
CA (1) CA2629545A1 (enExample)
WO (1) WO2007059203A2 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050149364A1 (en) * 2000-10-06 2005-07-07 Ombrellaro Mark P. Multifunction telemedicine software with integrated electronic medical record
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7599989B2 (en) * 2005-01-24 2009-10-06 Microsoft Corporation System and method for gathering and reporting screen resolutions of attendees of a collaboration session
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
CN117903302A (zh) 2005-11-30 2024-04-19 Abbvie 公司 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
US20070268294A1 (en) * 2006-05-16 2007-11-22 Stephen Troy Eagen Apparatus and method for topology navigation and change awareness
US20070294404A1 (en) * 2006-06-15 2007-12-20 International Business Machines Corporation Method and system for authorization and access control delegation in an on demand grid environment
US20080065999A1 (en) * 2006-09-13 2008-03-13 Majors Kenneth D Conferencing system with document access
US8418069B2 (en) * 2006-09-29 2013-04-09 International Business Machines Corporation Spinning off chat threads
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US9195996B1 (en) 2006-12-27 2015-11-24 Qurio Holdings, Inc. System and method for classification of communication sessions in a social network
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US7852819B2 (en) * 2007-03-01 2010-12-14 Meraki, Inc. Client operation for network access
US9274847B2 (en) * 2007-05-04 2016-03-01 Microsoft Technology Licensing, Llc Resource management platform
US8782527B2 (en) * 2007-06-27 2014-07-15 Microsoft Corp. Collaborative phone-based file exchange
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US7822841B2 (en) * 2007-10-30 2010-10-26 Modern Grids, Inc. Method and system for hosting multiple, customized computing clusters
EP2056563B1 (en) * 2007-11-05 2012-09-26 Alcatel Lucent Peer-to-peer network
US9117211B2 (en) * 2008-07-24 2015-08-25 International Business Machines Corporation System and method for correlating questions and answers in an instant messaging environment
US8655950B2 (en) * 2008-08-06 2014-02-18 International Business Machines Corporation Contextual awareness in real time collaborative activity alerts
US8838532B2 (en) * 2008-12-24 2014-09-16 At&T Intellectual Property I, L.P. Collaborative self-service contact architecture with automatic blog content mapping capability
GB2469501B (en) * 2009-04-16 2012-01-04 Appshare Ltd Method and system for network-based collaboration
US9390156B2 (en) * 2009-06-29 2016-07-12 International Business Machines Corporation Distributed directory environment using clustered LDAP servers
US20110142221A1 (en) * 2009-12-15 2011-06-16 At&T Intellectual Property I, L.P. System and method for automated group calling service based on key words
US8508575B2 (en) * 2010-03-31 2013-08-13 Sony Corporation Television system, television set and method for operating a television system
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
US9035997B2 (en) 2010-05-12 2015-05-19 Blue Jeans Network Systems and methods for real-time multimedia communications across multiple standards and proprietary devices
US9081633B2 (en) 2010-05-24 2015-07-14 Microsoft Technology Licensing, Llc Remote application connection sharing
EP2589183B1 (en) * 2010-06-29 2014-03-26 Telefonaktiebolaget L M Ericsson (publ) A method and an apparatus for evaluating network performance
US8558868B2 (en) * 2010-07-01 2013-10-15 Cisco Technology, Inc. Conference participant visualization
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
US9124757B2 (en) 2010-10-04 2015-09-01 Blue Jeans Networks, Inc. Systems and methods for error resilient scheme for low latency H.264 video coding
CA3179622C (en) * 2010-10-08 2025-08-05 Brian Lee Moffat Private data sharing system
US8380845B2 (en) 2010-10-08 2013-02-19 Microsoft Corporation Providing a monitoring service in a cloud-based computing environment
US8843632B2 (en) 2010-10-11 2014-09-23 Microsoft Corporation Allocation of resources between web services in a composite service
US8959219B2 (en) * 2010-10-18 2015-02-17 Microsoft Technology Licensing, Llc Dynamic rerouting of service requests between service endpoints for web services in a composite service
US8874787B2 (en) 2010-10-20 2014-10-28 Microsoft Corporation Optimized consumption of third-party web services in a composite service
US9369673B2 (en) 2011-05-11 2016-06-14 Blue Jeans Network Methods and systems for using a mobile device to join a video conference endpoint into a video conference
US9300705B2 (en) 2011-05-11 2016-03-29 Blue Jeans Network Methods and systems for interfacing heterogeneous endpoints and web-based media sources in a video conference
US9159037B2 (en) * 2011-06-14 2015-10-13 Genesys Telecommunications Laboratories, Inc. Context aware interaction
US9195971B2 (en) * 2011-07-12 2015-11-24 Salesforce.Com, Inc. Method and system for planning a meeting in a cloud computing environment
EP2555141A1 (en) * 2011-08-03 2013-02-06 Alcatel Lucent A method, a system, a server, a control element, a computer program and a computer program product for operating a power grid having decentralized control elements
EP2761492A4 (en) * 2011-09-28 2015-05-06 Apperian Inc COLLECTIVE COMMUNICATION SESSIONS THROUGH A BROADCAST NOTIFICATION NETWORK
US20130097244A1 (en) 2011-09-30 2013-04-18 Clearone Communications, Inc. Unified communications bridging architecture
DE102011117777B3 (de) * 2011-11-01 2013-01-31 Markus Lehnert System und Verfahren zur Bestimmung eines bevorzugten Kommunikationskanal
EP2629475B1 (en) 2012-02-16 2019-08-28 BlackBerry Limited Method and system for obtaining availability status for multiple sip users
JP6102575B2 (ja) * 2013-07-02 2017-03-29 富士通株式会社 性能測定方法、性能測定プログラム及び性能測定装置
US9392079B2 (en) 2013-07-19 2016-07-12 International Business Machines Corporation Directory service discovery and/or learning
US20150077509A1 (en) 2013-07-29 2015-03-19 ClearOne Inc. System for a Virtual Multipoint Control Unit for Unified Communications
US20170034235A1 (en) * 2015-07-27 2017-02-02 Browan Communications Inc. Electronic device, communication system and method for transmitting/receiving audio and video data
US10771508B2 (en) 2016-01-19 2020-09-08 Nadejda Sarmova Systems and methods for establishing a virtual shared experience for media playback
US9800931B1 (en) * 2016-06-08 2017-10-24 Cisco Technology, Inc. Adaptive screen layout for video conferencing
US9712570B1 (en) 2016-09-28 2017-07-18 Atlassian Pty Ltd Dynamic adaptation to increased SFU load by disabling video streams
WO2019036419A1 (en) * 2017-08-15 2019-02-21 Kalnik Matthew W NEW NICOTINE BINDING ANTIBODIES
CN110151762A (zh) * 2019-05-19 2019-08-23 青海大学 一种噻虫啉的新用途
EP4309374A1 (en) 2021-04-19 2024-01-24 Meta Platforms Technologies, Llc Wrist-wearable device for automatically switching between video and other calling modes based on sensor data at the wrist-wearable device, head-worn wearable devices for use therewith and for coordinated video capturing with the wrist-wearable device, and methods of use thereof
US11632454B2 (en) 2021-04-19 2023-04-18 Meta Platforms Technologies, Llc Head-worn wearable devices for automatically ceasing the capture of video data, and methods of use thereof
CN120457144A (zh) * 2022-11-10 2025-08-08 巴斯德研究所 产生作为α7烟碱乙酰胆碱受体的沉默和正变构调节剂的抗体

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977144A (en) 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
EP0659078B1 (en) 1992-08-31 2003-01-15 University Of Florida Research Foundation, Inc. Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system
UA54375C2 (uk) 1994-08-24 2003-03-17 Астра Актієболаг Спіро-азабіциклічні сполуки, способи їх одержання та фармацевтична композиція
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US7266686B1 (en) * 1996-05-09 2007-09-04 Two-Way Media Llc Multicasting method and apparatus
FR2756826B1 (fr) 1996-12-05 1999-01-08 Adir Nouveaux derives tetrahydropyridiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6323000B2 (en) 1996-12-20 2001-11-27 Clark A. Briggs Variant human α7 acetylcholine receptor subunit, and methods of production and uses thereof
JP2002502383A (ja) 1997-05-30 2002-01-22 ニューロサーアチ・アクティーゼルスカブ ニコチンＡＣｈレセプターに於けるコリン作動性リガンドとしての９−アザビシクロ（３．３．１）ノン−２−エン及びノナン誘導体
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
JP2003512290A (ja) 1997-09-10 2003-04-02 メルク エンド カムパニー インコーポレーテッド 家畜抗菌剤としての８ａ−アザライド
US6484196B1 (en) * 1998-03-20 2002-11-19 Advanced Web Solutions Internet messaging system and method for use in computer networks
US6459682B1 (en) * 1998-04-07 2002-10-01 International Business Machines Corporation Architecture for supporting service level agreements in an IP network
PT1083889E (pt) 1998-06-01 2004-04-30 Ortho Mcneil Pharm Inc Compostos de tetra-hidronaftaleno e sua utilizacao no tratamento de doencas neurodegenerativas
FR2786769B1 (fr) 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
FR2786770B1 (fr) 1998-12-04 2001-01-19 Synthelabo Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
FR2790474B1 (fr) 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
GB2349055B (en) * 1999-04-16 2004-03-24 Mitel Corp Virtual meeting rooms with spatial audio
DE60008866T2 (de) 1999-05-04 2005-01-27 Neurosearch A/S Heteroaryl diazabicycloalkene, deren herstellung und verwendung
WO2001073446A1 (en) 2000-03-29 2001-10-04 Synaptica Limited Alpha 7 nicotinic receptor screening assays
US6751404B1 (en) * 2000-04-13 2004-06-15 Forgent Networks, Inc. Method and apparatus for detecting processor congestion during audio and video decode
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
US6976066B1 (en) * 2000-05-22 2005-12-13 Microsoft Corporation Network and method for implementing network platform services for a computing device
US6610713B2 (en) 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
JP2002007294A (ja) * 2000-06-22 2002-01-11 Canon Inc 画像配信システム及び方法並びに記憶媒体
WO2002002564A1 (en) 2000-07-04 2002-01-10 Neurosearch A/S Aryl and heteroaryl diazabicycloalkanes, their preparation and use
JP4616971B2 (ja) 2000-07-18 2011-01-19 田辺三菱製薬株式会社 １−アザビシクロアルカン化合物およびその医薬用途
US20030037109A1 (en) * 2000-08-11 2003-02-20 Newman Harvey B. Virtual room videoconferencing system
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6479510B2 (en) 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6492386B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
WO2002015662A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
US7158534B2 (en) * 2000-11-30 2007-01-02 Imajet Communications, Inc. Unified distributed architecture for a multi-point video conference and interactive broadcast systems
ATE385497T1 (de) 2000-12-01 2008-02-15 Neurosearch As 3-substituierte quinuclidin-derivate und deren verwendung als nikotinischen agonisten
US20020086871A1 (en) 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
US7130883B2 (en) * 2000-12-29 2006-10-31 Webex Communications, Inc. Distributed network system architecture for collaborative computing
WO2002057275A1 (en) 2001-01-17 2002-07-25 University Of Kentucky Research Foundation Boron-containing nicotine analogs for use in the treatment of cns pathologies
US6479172B2 (en) 2001-01-26 2002-11-12 Xerox Corporation Electroluminescent (EL) devices
US20020133611A1 (en) * 2001-03-16 2002-09-19 Eddy Gorsuch System and method for facilitating real-time, multi-point communications over an electronic network
CA2341952A1 (en) 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
EP1419161A1 (en) 2001-08-24 2004-05-19 PHARMACIA & UPJOHN COMPANY Substituted-heteroaryl-7-aza 2.2.1]bicycloheptanes for the treatment of disease
JP2005527472A (ja) 2001-09-12 2005-09-15 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾患治療のための置換された７−アザ［２．２．１］ビシクロヘプタン
NZ531786A (en) 2001-10-02 2006-10-27 Upjohn Co Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
WO2003032897A2 (en) 2001-10-16 2003-04-24 Astrazeneca Ab Azabicyclic compounds for the treatment of fibromyalgia syndrome
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
BR0214016A (pt) 2001-11-09 2004-10-13 Upjohn Co Compostos azabicìclico-fenil-fundido heterocìclicos e seu uso como ligandos alfa 7 nachr
KR100411251B1 (ko) * 2001-11-28 2003-12-18 한국전자통신연구원 제한조건을 만족하는 다중 경로 배정방법
DE10211415A1 (de) 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
EP1581223B2 (en) * 2002-12-06 2016-05-25 The Feinstein Institute for Medical Research Inhibition of inflamation using alpha 7 receptor-binding cholinergic agonists
US7238715B2 (en) 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
US7680920B2 (en) * 2003-03-24 2010-03-16 Netiq Corporation Methods, systems and computer program products for evaluating network performance using diagnostic rules identifying performance data to be collected
US7415527B2 (en) * 2003-06-13 2008-08-19 Satyam Computer Services Limited Of Mayfair Centre System and method for piecewise streaming of video using a dedicated overlay network
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system

Also Published As

Publication number Publication date
US20090324588A1 (en) 2009-12-31
WO2007059203A2 (en) 2007-05-24
US20070156813A1 (en) 2007-07-05
AU2006315420B2 (en) 2010-07-15
JP2009515982A (ja) 2009-04-16
CN101355967A (zh) 2009-01-28
AU2006315420A1 (en) 2007-05-24
EP1957107A2 (en) 2008-08-20
US8524866B2 (en) 2013-09-03
CA2629545A1 (en) 2007-05-24
WO2007059203A3 (en) 2007-07-19
US8316104B2 (en) 2012-11-20

Similar Documents

Publication Publication Date Title
JP5303279B2 (ja) アルファ７ニコチン性受容体に対する抗体を使用した炎症性疾患の治療
JP5307708B2 (ja) ヒトｉｌ−６受容体に対する高親和性抗体
US8673305B2 (en) Methods of treatment with antibodies against the extracellular loops of C5aR
KR102194568B1 (ko) 항-mcam 항체 및 관련된 사용 방법
PT2115003E (pt) Anticorpos humanos que se ligam ao ligando 4 semelhante ao ligando delta humano
JP2015178534A (ja) 治療薬
US7807154B2 (en) Leptin antagonist and method for quantitative measurement of leptin
JP2009515827A5 (enExample)
WO2022095926A1 (zh) 靶向于白介素36r的抗体及其制备方法和应用
AU2003202297A1 (en) Anti-C5aR antibodies and uses thereof
EP3016977B1 (en) Human anti-il-32 antibodies
JPH08502164A (ja) オピオイドレセプター遺伝子
CN114805572A (zh) 抗原结合蛋白及其应用
CN110606892B (zh) 一种高亲和力高生物活性的lag-3抗体及其应用
CN110922483B (zh) 抗ccr5抗体及其在治疗肿瘤中的应用
JP2009096716A (ja) 抗ｃｃｌ２０抗体による自己免疫疾患の治療
CN119604529A (zh) 抗体、其抗原结合片段及其药物用途
WO2024255683A1 (zh) 抗bdca2抗体
CN118271438A (zh) 抗cgrp抗体或其抗原结合片段及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091106

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20091113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130524

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130606

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130624

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees